Welcome to our dedicated page for Delcath Sys news (Ticker: DCTH), a resource for investors and traders seeking the latest updates and insights on Delcath Sys stock.
Delcath Systems, Inc. develops interventional oncology products for primary and metastatic liver cancers. Its core products include HEPZATO KIT, a melphalan and Hepatic Delivery System combination product approved in the United States as a liver-directed treatment for adult patients with metastatic uveal melanoma, and CHEMOSAT Hepatic Delivery System for Melphalan used in percutaneous hepatic perfusion.
Recurring news covers quarterly operating results, HEPZATO KIT and CHEMOSAT revenue, clinical publications from studies such as FOCUS and CHOPIN, presentations at oncology and interventional radiology meetings, guideline recognition, and studies of melphalan-based percutaneous hepatic perfusion in liver-dominant cancers. Company updates also address FDA-approved product status, European clinical practice references, and capital actions such as common-stock repurchases.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Delcath Systems (NASDAQ: DCTH) announced an amendment to its loan agreement with Avenue Venture Opportunities Fund, allowing for an interest-only period from March 31, 2023 to September 30, 2023. This defers approximately $4.3 million in principal payments. The company may extend this period to December 31, 2023 if it secures FDA approval for the HEPZATO Kit and raises at least $10 million through equity sales. Delcath will issue 34,025 warrants to Avenue with an exercise price of $0.01. This support aims to enhance the company's cash runway ahead of its PDUFA date on August 14, 2023.
Delcath Systems, Inc. (Nasdaq: DCTH) has completed a $25 million private placement with the potential for an additional $60 million based on milestone achievements. The financing, led by Vivo Capital and supported by various investors, is intended to fund operations through the anticipated FDA PDUFA date of August 14, 2023 for its product HEPZATO. The total proceeds are expected to cover working capital and general corporate purposes, with warrants providing further potential funding. The deal enables funding for commercialization if HEPZATO receives approval.
Delcath Systems, Inc. (DCTH) announced its fourth quarter and full year 2022 results, emphasizing significant milestones, including FDA acceptance of the NDA resubmission for Hepzato Kit® with a PDUFA date of August 14, 2023. The company secured $25 million in upfront financing, with potential additional funding of up to $60 million. Product revenue increased to $0.6 million in Q4 2022, up from $0.2 million in Q4 2021. However, Delcath reported a net loss of $8.5 million in Q4 2022, increasing its annual net loss to $36.5 million. As of December 31, 2022, cash holdings decreased to $11.8 million from $26.9 million the previous year.